Media & Investors
Get the latest news and discover our mission and vision. Meet our company speakers and get in touch for press and investor inquiries.
Get the latest news and discover our mission and vision. Meet our company speakers and get in touch for press and investor inquiries.
Read the latest of myTomorrows
فبراير 26, 2025
Clinical trial matchmaker myTomorrows has struck up a partnership with personal health recordkeeper Patients Know Best (PKB) so that UK participants can search for possible trials to join.
فبراير 25, 2025
myTomorrows and Patients Know Best (PKB) have partnered to enable UK patients with unmet medical needs to conduct more efficient searches for further treatment options.
فبراير 17, 2025
Romina Dibra MD, expert at healthcare technology company myTomorrows, has shared her insight into the most recent technological advancements in ALS Management and how they aim to enhance early diagnosis, significantly improve quality of life and provide more effective, personalized treatments.
فبراير 14, 2025
Angela Sarmiento Betancourt, MD. at myTomorrows, shares her insights into current strategies and patient-centric research advancements for the treatment of type 1 diabetes.
فبراير 7, 2025
With the goal of streamlining industry-wide clinical trial recruitment and improving patient outcomes, myTomorrows unveils its next major AI-powered technological advancement.
فبراير 7, 2025
Michel van Harten, MD, discusses the importance of accessibility within oncological clinical trials which pave the way for better patient outcomes and accelerate critical cancer treatments.
فبراير 6, 2025
Designed to streamline clinical trial recruitment, the platform supercharges how physicians search, pre-screen, and refer patients — helping trial sponsors accelerate enrollment, enhance diversity, and optimize operations.
فبراير 3, 2025
Michel van Harten, MD, discusses how physicians and BioPharma companies and patient advocacy groups can address trust challenges by actively engaging with patient communities to empower them to participate in shaping the future of medicine.
فبراير 3, 2025
Danny den Hamer, myTomorrows Product Manager discussed the use of AI to improve oncology care and how it can support finding the right clinical trials for patients.
يناير 20, 2025
Angela Sarmiento Betancourt MD, Medical Affairs Manager shares her insights on the key red flags of cervical cancer, including some common symptoms and how to spot them early.
يناير 15, 2025
Michel van Harten, MD, discusses how by addressing structural barriers and expanding awareness can help boost participation in clinical trials, potentially advance the development and approval of new drugs, and inform accessibility for patients with rare diseases.
يناير 13, 2025
Michel van Harten, MD, contributes to the discussion noting the emerging importance of decentralized trial designs, enhanced community engagement and the important role of patient advocacy groups.
يناير 3, 2025
In this discussion, Jytte van Huijstee, Director of Clinical Trial Operations at myTomorrows, shares insights on technology’s role in clinical trials, addressing recruitment gaps, and fostering diversity.
ديسمبر 5, 2024
myTomorrows expands into APAC to Improve access to Clinical Trials and Programs across the region
ديسمبر 4, 2024
Health tech company myTomorrows cuts ribbon at India operations hub, looks to expand clinical trial access in Asia
سبتمبر 30, 2024
myTomorrows and CureLGMD2i Partnership to Improve Access to Clinical Trials for Limb Girdle Muscular Dystrophy
سبتمبر 25, 2024
How to advance diversity, equity and inclusion in clinical trial recruitment
سبتمبر 9, 2024
CEO of myTomorrows, Michel van Harten M.D. discusses the dangerous implications of medical misinformation, not only for patients but also for healthcare professionals and the wider BioPharma industry.
سبتمبر 4, 2024
Under a new partnership, CureLGMD2i will leverage myTomorrows' extensive search engine of ongoing clinical trials to provide patients, caregivers, and healthcare professionals with up-to-date, accessible information about pre-approval treatments that may be relevant to them.
أبريل 9, 2024
A new collaboration announced today will help provide brain tumour patients and physicians with accurate information about clinical trials in a bid to improve patient access.
أبريل 9, 2024
Affecting 80,000 people in England, 12% of brain tumour patients survive beyond five years of diagnosis. myTomorrows has announced a new partnership with a UK-based charity, brainstrust, to support individuals living with brain cancer.
أبريل 5, 2024
Affecting 80,000 people in England, 12% of brain tumour patients survive beyond five years of diagnosis. myTomorrows has announced a new partnership with a UK-based charity, brainstrust, to support individuals living with brain cancer.
أبريل 4, 2024
myTomorrows and UK brainstrust plans to increase patient recruitment in brain tumour clinical trials by increasing awareness.
أبريل 4, 2024
myTomorrows, a global health technology company connecting patients with all possible treatment options, today announced a new partnership with brainstrust, a UK-based charity that helps people living with a brain tumor reach their potential and thrive.
أبريل 1, 2024
Certain features, commonplace on most e-commerce platforms, can help transform clinical trial search databases.
مارس 15, 2024
A non-profit organisation representing the amyotrophic lateral sclerosis (ALS) community in the US is taking a digital approach to connecting patients with suitable clinical trials.
مارس 14, 2024
Partnership with leading US-based ALS patient advocacy group furthers myTomorrows' mission of ensuring that patients confronting life-threatening diseases are aware of all possible treatment options
ديسمبر 6, 2023
CEO Michel van Harten speaks with Clinical Trial Vanguard about myTomorrows’ innovative use of AI in physician-led clinical trial screening.
نوفمبر 29, 2023
"I started myTomorrows in 2012 after losing my father to an aggressive form of lung cancer. As a physician and founder of several biotech companies, I thought I could help him find and access a treatment in development. But I was surprised at how complicated and slow the process was. I decided this had to change, so I dedicated myself to creating an easier and faster way for patients to access treatments in development.
We have grown a lot since then, and our team of experts has helped patients in over 60 countries. But our guiding principle remains the same: We believe every patient should have access to all possible treatment options. We are here for you, so let us know how we can help."
سبتمبر 13, 2023
myTomorrows teams up with digital health innovator Congenica, highlighting tech’s role in the future of healthcare.
يوليو 25, 2023
myTomorrows shares insights on discovering clinical trials for cancer.
يونيو 28, 2023
myTomorrows’ CEO explores the power of AI for matching patients with the clinical trials right for them
أبريل 27, 2023
Fierce Biotech shares launch of myTomorrows exciting new AI-backed patient pre-screening tool.
أبريل 26, 2023
The global Health technology company myTomorrows said it launched the beta version of TrialSearch AI, a first-of-its-kind artificial intelligence tool to broaden physician insights into clinical trials and expanded access programs in the myTomorrows’ curated database.
Our experts have been pulled in to discuss a wide range of topics, from patient-centricity, clinical trials, expanded access, innovation, healthcare technology, artificial intelligence, and many more. Get in touch with them.
myTomorrows aims to break barriers for eligible patients seeking information about clinical trials and we support referrals to trial sites. When patients are not eligible to clinical studies, we can help them and their physicians to further explore and navigate the complexities of expanded access programs.
Our digital platform connects all stakeholders in pre-approval access and supports both clinical trial and expanded access workflows.
myTomorrows operates globally and has offices in Amsterdam and New York City.
We’ve helped
A community of
Trusted by
Media inquiries
mytomorrows@headline.media
[wpforms id=”2662″]
